In this recent study they sought to determine if combining drugs previously shown to improve lifespan would have greater impact than any individual drug, a diet containing rapamycin at 14 ppm, acarbose at 1000 ppm, and phenylbutyrate at 1000 ppm was fed to 20-month-old C57BL/6 and HET3 4-way cross mice of both sexes for three months.
Mice fed the cocktail diet showed a strain and gender-dependent phenotype consistent with healthy aging including decreased body fat and blood glucose, improved cognition, and increased grip strength and walking ability compared to mice fed individual drug or control diets.
A cocktail diet containing one-half dosing of each compound was overall less effective than the full dose. The composite age-related lesion score of heart, lungs, liver and kidney was decreased in mice fed the cocktail diet compared to mice fed individual drug or control diets suggesting an interactive advantage of the three drugs.
Senescence and inflammatory cytokine levels in kidneys from mice fed the cocktail diet were lower than in kidneys from mice fed control diet, and consistent with low expression levels in kidneys from young untreated mice, suggesting the cocktail diet delayed aging partly by senolytic and anti-inflammatory effects.
More information on phenylbutyrate, also known as sodium phenylbutyrate:
Generic name: sodium phenylbutyrate (SOE dee um FEN il BUE ti rate)
Brand names: Buphenyl, SPB11
Sodium phenylbutyrate is an FDA approved orphan drug, marketed by Ucyclyd Pharma under the trade name Buphenyl, by Swedish Orphan International (Sweden) as Ammonaps, aby Fyrlklövern Scandinavia as triButyrate and by Scandinavian Formulas, Inc. (Sellersville, PA)
Read the full story here: Cocktail of Rapamycin, Acarbose and Phenylbutyrate (Part 2)